Patents by Inventor Charles Romeo
Charles Romeo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080096247Abstract: Nucleic acids encoding preduramycin and produramycin are described, along with recombinant nucleic acids host cells containing the same and methods of use thereof, such as for the manufacture of the lantibiotic duramycin.Type: ApplicationFiled: April 3, 2007Publication date: April 24, 2008Inventors: Luis Molina, Charles Romeo
-
Patent number: 7320787Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: May 20, 2002Date of Patent: January 22, 2008Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 7094599Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: GrantFiled: August 24, 2001Date of Patent: August 22, 2006Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Publication number: 20060141564Abstract: Nucleic acids encoding preduramycin and produramycin are described, along with recombinant nucleic acids and host cells containing the same and methods of use thereof, such as for the manufacture of the lantibiotic duramycin.Type: ApplicationFiled: September 22, 2003Publication date: June 29, 2006Inventors: Luis Molina, Charles Romeo
-
Patent number: 7049136Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: February 2, 1999Date of Patent: May 23, 2006Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6753162Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed is a second method of treating HIV in a mammal involving administering to the mammal an effective amount of therapeutic cells expressing a membrane-bound, proteinaceous chimeric receptor comprising an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection.Type: GrantFiled: February 24, 1995Date of Patent: June 22, 2004Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Publication number: 20040005334Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: ApplicationFiled: February 2, 1999Publication date: January 8, 2004Inventors: BRIAN SEED, CHARLES ROMEO, WALDEMAR KOLANUS
-
Publication number: 20030138410Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: ApplicationFiled: August 24, 2001Publication date: July 24, 2003Inventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Publication number: 20030053994Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: ApplicationFiled: May 20, 2002Publication date: March 20, 2003Inventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Publication number: 20020176851Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: ApplicationFiled: February 25, 2002Publication date: November 28, 2002Inventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6410014Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: June 15, 1999Date of Patent: June 25, 2002Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6392013Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: July 7, 1997Date of Patent: May 21, 2002Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6284240Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: GrantFiled: December 22, 1998Date of Patent: September 4, 2001Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Patent number: 6004811Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are calls which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: February 24, 1995Date of Patent: December 21, 1999Assignee: The Massachussetts General HospitalInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 5912170Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: February 24, 1995Date of Patent: June 15, 1999Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 5851828Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: GrantFiled: August 2, 1994Date of Patent: December 22, 1998Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Patent number: 5843728Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: April 5, 1995Date of Patent: December 1, 1998Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus